Integumen study supports cost-saving potential of Labskin technology

Labskin is a lab-grown skin which cosmetic companies can use to test their latest products in a real-world setting

Integumen -

A recent study has shown that Integumen PLC’s (LON:SKIN) Labskin technology can help cosmetic companies reduce development time, clinical errors and costs.

Researchers took swabs of skin from the cheeks of 16 healthy volunteers and then cloned them into 54 Labskin subjects.

The live bacteria, virus and fungi on those subjects was sustained for up to 14 days at the company’s laboratory in York.

READ: Integumen posts 1,200% rise in first-half revenue as big cosmetics companies sign up

The Labskin AI virtual model then analysed this microbiome data, which showed that all of the test subjects were within a range of 10% of the human volunteers’ control skin.

Bosses said the results of the study, which will be presented later today at a conference in California, validated Labskin’s ability to test multiple skincare products in parallel, without losing their original characteristics.

“This allows multiple skincare products or topical drug samples to be tested on the same subject, at the same time, thus substantially reducing development time, clinical error and clinical trial supervision costs.”

Chief executive Gerry Brandon added: “By de-risking each stage of the traditional topical drug and skincare product development process, the Labskin cloning service makes it economic for industry to research and explore new treatments by allowing agile development and a cost-effective ‘fast fail’ protocols on disposable human-skin test subjects cloned from healthy human volunteers.

“This breakthrough study clearly supports our commercial strategy and demonstrates Labskin's ability to deliver healthy and damaged skin testing 'as services' using a proven 'software as a service' business model already adopted by, and proven, in other industries.”

Integumen shares were up 1.3% to 2.0p on Thursday morning.

Quick facts: Integumen

Price: 1.7301 GBX

Market: AIM
Market Cap: £18.66 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...



Morning Report: FTSE 100 nervous, gold higher as second wave concerns resurface

Headlines from the Proactive UK newsroom. FTSE 100 dipped as the rise in coronavirus infections in Germany and China unsettled the market. The index dropped 25 to 6,266. Gold rose to a one month high of US$1,750 per ounce overnight as Asian markets wobbled on the coronavirus scare. Bulls of...

1 week, 3 days ago

2 min read